メディカルプレスセンター QLifePro

ニュース
添付文書
薬の臨床実感＆助言集

Brentuximab Vedotin

Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Brentuximab Vedotin ECHELON-2 Clinical Trial Evaluating ADCETRIS in Frontline CD30-Expressing Peripheral T-Cell Seattle Genetics and Takeda Announce Positive

2018年10月01日

European Commission Approves ADCETRIS® (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma after One Prior Systemic Therapy– Providing an Innovative Treatment Option to Patients

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬遺伝学　 TimeLine: Brentuximab Vedotin European Commission Approves ADCETRIS for CD30-Positive Cutaneous T-Cell Lymphoma after One Prior Systemic Therapy Providing an Innovative Treatment Option

2018年01月22日

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬遺伝学　 TimeLine: Brentuximab Vedotin ECHELON-1 Clinical Trial Evaluating ADCETRIS in Frontline Advanced Hodgkin Lymphoma Takeda and Seattle Genetics to Present Positive

2017年12月10日

武田的ADCETRIS® (brentuximab vedotin)获得CHMP肯定意见，用于治疗CD30阳性皮肤T细胞淋巴瘤

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Brentuximab Vedotin

2017年11月17日

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Brentuximab Vedotin for CD30-Positive Cutaneous T-Cell Lymphoma Takeda Receives Positive CHMP Opinion for ADCETRIS

2017年11月15日

$Seattle Genetics and Takeda Announce Publication in Blood of Final Long-Term Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma$

Seattle Genetics and Takeda Announce Publication in Blood of Final Long-Term Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Brentuximab Vedotin Final Long-Term Survival Data from ADCETRIS Pivotal Phase 2 Clinical Trial in Relapsed Refractory Systemic Anaplastic Large Cell Lymphoma Seattle Genetics and Takeda Announce Publication

2017年10月03日

Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma

その他ヘルスヘルスケアヘルス一般腫瘍学臨床試験製薬遺伝学　 TimeLine: Brentuximab Vedotin ECHELON-1 Clinical Trial Evaluating ADCETRIS in Frontline Advanced Hodgkin Lymphoma Takeda and Seattle Genetics Announce Positive

2017年06月26日

Takeda and Seattle Genetics Announce Lancet Publication of Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬遺伝学　 TimeLine: Brentuximab Vedotin for CD30-Positive Cutaneous T-Cell Lymphoma Phase 3 ALCANZA Clinical Trial Data Takeda and Seattle Genetics Announce Lancet

2017年06月07日

Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma

バイオテクノロジーヘルスケア幹細胞腫瘍学臨床試験製薬　 TimeLine: Brentuximab Vedotin for CD30-Expressing Cutaneous T-Cell Lymphoma Takeda and Seattle Genetics Report Positive Phase Trial Data of ADCETRIS

2016年12月04日

Seattle Genetics and Takeda Complete Enrollment of Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-cell Lymphoma

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Brentuximab Vedotin Clinical Trial Evaluating ADCETRIS in Frontline Mature T-cell Lymphoma Seattle Genetics and Takeda Complete Enrollment

2016年11月08日